RAFAEL HOLDINGS, INC. Unrealized Gain (Loss) on Derivatives
RAFAEL HOLDINGS, INC. (RFL) reported Unrealized Gain (Loss) on Derivatives of $1.19 million for the 12-month period ending 2024-07-31, per its 10-K/A filed 2024-12-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2024-12-20
- RAFAEL HOLDINGS, INC. unrealized gain (loss) on derivatives for fiscal 2024 was $1.19M.
- RAFAEL HOLDINGS, INC. unrealized gain (loss) on derivatives for fiscal 2022 was $31.85M, a 3190.29% increase from fiscal 2021.
- RAFAEL HOLDINGS, INC. unrealized gain (loss) on derivatives for fiscal 2021 was $968.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|
| 2024-07-31 | $1.19M 10-K/A · filed 2024-12-20 |
| 2022-07-31 | $31.85M 10-K · filed 2022-10-31 |
| 2021-07-31 | $968.00K 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |